Response to Aminoglutethimide and Cortisone Acetate in Advanced Prostatic Cancer
Author Information
Author(s): B.A.J. Ponder, R.J. Shearer, R.D. Pocock, J. Miller, D. Easton, C.E.D. Chilvers, M. Dowsett, S.L. Jeffcoate
Primary Institution: Royal Marsden Hospital
Hypothesis
Can aminoglutethimide plus cortisone acetate provide a subjective response in patients with advanced prostatic cancer who have failed previous treatments?
Conclusion
Aminoglutethimide plus cortisone acetate is a useful addition to the treatment for patients with advanced prostatic cancer, providing symptom relief for about half of the patients evaluated.
Supporting Evidence
- Nineteen out of 40 patients obtained a subjective response.
- Seventeen of the 19 responses were apparent within 2 weeks of starting treatment.
- The median duration of response was 8 months.
- Treatment was well tolerated with mild side effects in most patients.
Takeaway
This study tested a new treatment for men with advanced prostate cancer who didn't get better with other treatments. About half of the men felt less pain after taking the new medicine.
Methodology
A multi-centre study evaluating subjective responses to treatment in patients with advanced prostatic cancer.
Potential Biases
Potential bias due to the subjective nature of the response assessment.
Limitations
The study had a small sample size and focused on subjective responses rather than objective tumor measurements.
Participant Demographics
The majority of evaluable patients were under 75 years of age, with a performance status of 1 or 2.
Statistical Information
P-Value
p=0.01, p=0.05, p=0.02
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website